vs
BROADWIND, INC.（BWEN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
BROADWIND, INC.的季度营收约是REGENXBIO Inc.的1.2倍（$37.7M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs 12.4%），BROADWIND, INC.自由现金流更多（$-187.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 0.2%）
Broadwind Inc.是一家总部位于美国的工业制造企业，主营重型结构部件、齿轮系统的生产及相关售后服务，业务覆盖可再生能源、基础设施与重工业领域，主要为北美市场的风电项目、公用事业能源工程等供应核心零部件。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BWEN vs RGNX — 直观对比
营收规模更大
BWEN
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出30.6%
12.4%
自由现金流更多
BWEN
多$52.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.7M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | 8.8% | — |
| 营业利润率 | -0.2% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 12.4% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BWENRGNX
| Q4 25 | $37.7M | $30.3M | ||
| Q3 25 | $44.2M | $29.7M | ||
| Q2 25 | $39.2M | $21.4M | ||
| Q1 25 | $36.8M | $89.0M | ||
| Q4 24 | $33.6M | $21.2M | ||
| Q3 24 | $35.5M | $24.2M | ||
| Q2 24 | $36.5M | $22.3M | ||
| Q1 24 | $37.6M | $15.6M |
净利润BWENRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $7.5M | $-61.9M | ||
| Q2 25 | $-989.0K | $-70.9M | ||
| Q1 25 | $-370.0K | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $74.0K | $-59.6M | ||
| Q2 24 | $482.0K | $-53.0M | ||
| Q1 24 | $1.5M | $-63.3M |
毛利率BWENRGNX
| Q4 25 | 8.8% | — | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | 10.1% | — | ||
| Q1 25 | 11.7% | — | ||
| Q4 24 | 11.3% | 70.2% | ||
| Q3 24 | 14.6% | 48.8% | ||
| Q2 24 | 15.3% | 52.5% | ||
| Q1 24 | 17.6% | 72.6% |
营业利润率BWENRGNX
| Q4 25 | -0.2% | -190.0% | ||
| Q3 25 | 19.7% | -176.3% | ||
| Q2 25 | -0.4% | -296.3% | ||
| Q1 25 | 0.5% | 13.6% | ||
| Q4 24 | -0.9% | -242.1% | ||
| Q3 24 | 3.3% | -256.6% | ||
| Q2 24 | 3.4% | -251.3% | ||
| Q1 24 | 5.5% | -408.8% |
净利率BWENRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 16.9% | -208.3% | ||
| Q2 25 | -2.5% | -331.8% | ||
| Q1 25 | -1.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 0.2% | -246.3% | ||
| Q2 24 | 1.3% | -237.7% | ||
| Q1 24 | 4.0% | -405.4% |
每股收益（稀释后）BWENRGNX
| Q4 25 | $-0.03 | $-1.30 | ||
| Q3 25 | $0.32 | $-1.20 | ||
| Q2 25 | $-0.04 | $-1.38 | ||
| Q1 25 | $-0.02 | $0.12 | ||
| Q4 24 | $-0.04 | $-0.99 | ||
| Q3 24 | $0.00 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $456.0K | $230.1M |
| 总债务越低越好 | $10.1M | — |
| 股东权益账面价值 | $66.3M | $102.7M |
| 总资产 | $116.8M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资BWENRGNX
| Q4 25 | $456.0K | $230.1M | ||
| Q3 25 | $1.2M | $274.2M | ||
| Q2 25 | $1.0M | $323.3M | ||
| Q1 25 | $1.2M | $267.9M | ||
| Q4 24 | $7.7M | $234.7M | ||
| Q3 24 | $1.4M | $255.5M | ||
| Q2 24 | $938.0K | $290.4M | ||
| Q1 24 | $1.1M | $338.7M |
总债务BWENRGNX
| Q4 25 | $10.1M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $26.1M | — | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $16.9M | — | ||
| Q2 24 | $18.0M | — | ||
| Q1 24 | $7.7M | — |
股东权益BWENRGNX
| Q4 25 | $66.3M | $102.7M | ||
| Q3 25 | $66.9M | $161.5M | ||
| Q2 25 | $59.0M | $213.7M | ||
| Q1 25 | $59.3M | $274.2M | ||
| Q4 24 | $59.4M | $259.7M | ||
| Q3 24 | $59.6M | $301.4M | ||
| Q2 24 | $59.1M | $348.3M | ||
| Q1 24 | $58.0M | $390.7M |
总资产BWENRGNX
| Q4 25 | $116.8M | $453.0M | ||
| Q3 25 | $119.6M | $525.2M | ||
| Q2 25 | $130.5M | $581.0M | ||
| Q1 25 | $129.3M | $490.9M | ||
| Q4 24 | $128.3M | $466.0M | ||
| Q3 24 | $125.1M | $519.1M | ||
| Q2 24 | $122.5M | $569.4M | ||
| Q1 24 | $123.1M | $629.2M |
负债/权益比BWENRGNX
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $857.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-187.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -0.5% | -174.0% |
| 资本支出强度资本支出/营收 | 2.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-19.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BWENRGNX
| Q4 25 | $857.0K | $-52.3M | ||
| Q3 25 | $4.3M | $-56.0M | ||
| Q2 25 | $-12.5M | $-49.3M | ||
| Q1 25 | $-8.0M | $33.6M | ||
| Q4 24 | $14.8M | $-31.6M | ||
| Q3 24 | $2.4M | $-40.5M | ||
| Q2 24 | $-9.3M | $-45.5M | ||
| Q1 24 | $5.9M | $-55.5M |
自由现金流BWENRGNX
| Q4 25 | $-187.0K | $-52.8M | ||
| Q3 25 | $3.8M | $-56.5M | ||
| Q2 25 | $-13.7M | $-49.7M | ||
| Q1 25 | $-9.0M | $32.6M | ||
| Q4 24 | $14.5M | $-32.7M | ||
| Q3 24 | $1.7M | $-40.9M | ||
| Q2 24 | $-10.1M | $-46.0M | ||
| Q1 24 | $4.1M | $-56.0M |
自由现金流率BWENRGNX
| Q4 25 | -0.5% | -174.0% | ||
| Q3 25 | 8.6% | -189.9% | ||
| Q2 25 | -34.8% | -232.8% | ||
| Q1 25 | -24.3% | 36.6% | ||
| Q4 24 | 43.1% | -154.2% | ||
| Q3 24 | 4.8% | -168.9% | ||
| Q2 24 | -27.6% | -206.2% | ||
| Q1 24 | 10.9% | -358.5% |
资本支出强度BWENRGNX
| Q4 25 | 2.8% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 3.1% | 1.8% | ||
| Q1 25 | 2.5% | 1.2% | ||
| Q4 24 | 1.0% | 5.1% | ||
| Q3 24 | 2.1% | 1.3% | ||
| Q2 24 | 2.2% | 2.1% | ||
| Q1 24 | 4.6% | 3.6% |
现金转化率BWENRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 32.99× | — | ||
| Q2 24 | -19.26× | — | ||
| Q1 24 | 3.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWEN
| Heavy Fabrications | $21.6M | 57% |
| Industrial Solutions | $9.4M | 25% |
| Gearing | $7.0M | 19% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
